BioSpace News Archive

Business

Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

Equillium grants Ono an option to purchase rights to itolizumab.

December 6, 2022
·
12 min read
Drug Development

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc. today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure.

December 6, 2022
·
4 min read
Drug Development

Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

Gossamer Bio, Inc. today announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).

December 6, 2022
·
9 min read
Genetown

Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Entact Bio today announced it has raised $81 million in Series A financing to advance its proprietary Encompass™ platform for developing enhancement-targeting chimeric (ENTAC™) molecules.

December 6, 2022
·
5 min read
Business

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody$500 Million Upfront Payment to Activate the Partnership for Ivonescimab

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab.

December 6, 2022
·
17 min read
Business

Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board

BiondVax Pharmaceuticals Ltd. today announced that Professor Dr. med. Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).

December 6, 2022
·
6 min read
FDA

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Virax Biolabs Group Limited announced today that their supplier has received an Emergency Use Authorization (“EUA”) from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test (the “Test”).

December 6, 2022
·
3 min read
Genetown

Study finds link between air pollution and increased depression symptoms in people with bipolar disorder

Researchers at University College London (UCL) published the results of the first study to find that short-term air pollution exposure is associated with acutely increased depression symptoms in people with bipolar disorder.

December 6, 2022
·
4 min read
Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced today that a clinical study conducted by its wholly owned subsidiary KGK Science Inc. (“KGK”), has shown positive results of UP446 supplementation in helping mount a robust immune response following influenza vaccination.

December 6, 2022
·
6 min read
Business

Click Therapeutics Announces Collaboration with the Massachusetts Medical Society to Enable Advancement in Medical Innovation

Click Therapeutics, Inc. today announced their partnership with The Massachusetts Medical Society (“MMS”), a statewide professional association for physicians and medical students, supporting more than 25,000 members.

December 6, 2022
·
3 min read